Viking Therapeutics announced its financial results for the first quarter ended March 31, 2025, on April 23, 2025. The company reported a net loss of $45.6 million, or $0.41 per share, for the quarter. This represents an increase from the net loss of $27.4 million, or $0.26 per share, in the corresponding period of 2024.
Research and development expenses significantly increased to $41.4 million for the three months ended March 31, 2025, compared to $24.1 million in Q1 2024. This rise was primarily driven by increased spending on manufacturing for drug candidates and clinical studies. General and administrative expenses also grew to $14.1 million from $10.0 million year-over-year.
Despite the increased losses reflecting accelerated pipeline development, Viking maintained a strong cash position. The company held cash, cash equivalents, and short-term investments of $852 million as of March 31, 2025. This robust balance provides sufficient funding to support operations through at least June 30, 2026, enabling aggressive clinical execution.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.